Friday, 6 October 2017

Bayer sticks by Xarelto sales estimate despite study setback

FRANKFURT/BERLIN (Reuters) - Bayer stood by its peak sales estimate for clot prevention drug Xarelto after the pill disappointed in a late-stage trial to test prevention of repeat strokes.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)